Build Your Comparison

Side-by-side financial analysis
NYXH logo
NYXH
INSP logo
INSP
LIVN logo
LIVN
AVAV logo
AVAV
NVCR logo
NVCR
Try popular comparisons:

Stock Comparison

NYXH vs INSP vs LIVN vs AVAV vs NVCR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NYXH
Nyxoah S.A.

Medical - Instruments & Supplies

HealthcareNASDAQ • BE
Market Cap$52M
5Y Perf.-94.2%
INSP
Inspire Medical Systems, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.23B
5Y Perf.-82.0%
LIVN
LivaNova PLC

Medical - Devices

HealthcareNASDAQ • GB
Market Cap$4.36B
5Y Perf.-6.5%
AVAV
AeroVironment, Inc.

Aerospace & Defense

IndustrialsNASDAQ • US
Market Cap$8.52B
5Y Perf.+54.6%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.02B
5Y Perf.-91.3%

NYXH vs INSP vs LIVN vs AVAV vs NVCR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NYXH logoNYXH
INSP logoINSP
LIVN logoLIVN
AVAV logoAVAV
NVCR logoNVCR
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - DevicesAerospace & DefenseMedical - Instruments & Supplies
Market Cap$52M$1.23B$4.36B$8.52B$2.02B
Revenue (TTM)$16M$915M$1.43B$1.61B$674M
Net Income (TTM)$-86M$131M$107M$-224M$-173M
Gross Margin48.3%85.8%67.5%21.8%75.2%
Operating Margin-5.3%5.6%13.4%-8.3%-27.2%
Forward P/E47.6x18.7x59.2x
Total Debt$42M$32M$473M$64M$290M
Cash & Equiv.$30M$105M$636M$41M$103M

NYXH vs INSP vs LIVN vs AVAV vs NVCRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NYXH
INSP
LIVN
AVAV
NVCR
StockApr 21Jun 26Return
Nyxoah S.A. (NYXH)1005.8-94.2%
Inspire Medical Sys… (INSP)10018.0-82.0%
LivaNova PLC (LIVN)10093.5-6.5%
AeroVironment, Inc. (AVAV)100154.6+54.6%
NovoCure Limited (NVCR)1008.7-91.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: NYXH vs INSP vs LIVN vs AVAV vs NVCR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INSP leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. LivaNova PLC is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. NYXH also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇INSP emerged as the overall leader. Track its performance:
NYXH
Nyxoah S.A.
The Growth Play

NYXH ranks third and is worth considering specifically for growth exposure.

  • Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
  • 121.6% revenue growth vs NVCR's 8.3%
Best for: growth exposure
INSP
Inspire Medical Systems, Inc.
The Income Pick

INSP carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.16
  • Lower volatility, beta 1.16, Low D/E 4.1%, current ratio 6.08x
  • Beta 1.16, current ratio 6.08x
  • 14.3% margin vs NYXH's -5.3%
Best for: income & stability and sleep-well-at-night
LIVN
LivaNova PLC
The Value Play

LIVN is the #2 pick in this set and the best alternative if value and momentum is your priority.

  • Better valuation composite
  • +70.3% vs NYXH's -81.6%
Best for: value and momentum
AVAV
AeroVironment, Inc.
The Long-Run Compounder

AVAV is the clearest fit if your priority is long-term compounding.

  • 445.9% 10Y total return vs INSP's 70.9%
Best for: long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNYXH logoNYXH121.6% revenue growth vs NVCR's 8.3%
ValueLIVN logoLIVNBetter valuation composite
Quality / MarginsINSP logoINSP14.3% margin vs NYXH's -5.3%
Stability / SafetyINSP logoINSPBeta 1.16 vs NVCR's 2.21, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)LIVN logoLIVN+70.3% vs NYXH's -81.6%
Efficiency (ROA)INSP logoINSP15.2% ROA vs NYXH's -80.8%, ROIC 6.0% vs -76.4%

NYXH vs INSP vs LIVN vs AVAV vs NVCR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Defense Stocks Theme

These companies are key players in the Defense Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NYXHNyxoah S.A.

Segment breakdown not available.

INSPInspire Medical Systems, Inc.
FY 2025
Operating Segment
100.0%$912M
LIVNLivaNova PLC
FY 2025
Cardiopulmonary Segment
57.0%$785M
Neuromodulation Segment
43.0%$593M
AVAVAeroVironment, Inc.
FY 2024
Product sales
81.7%$586M
Contract services
18.3%$131M
NVCRNovoCure Limited

Segment breakdown not available.

NYXH vs INSP vs LIVN vs AVAV vs NVCR — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLIVNLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

LIVN leads this category, winning 3 of 6 comparable metrics.

AVAV is the larger business by revenue, generating $1.6B annually — 98.7x NYXH's $16M. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCAVAV logoAVAVAeroVironment, In…NVCR logoNVCRNovoCure Limited
RevenueTrailing 12 months$16M$915M$1.4B$1.6B$674M
EBITDAEarnings before interest/tax-$81M$62M$220M$82M-$165M
Net IncomeAfter-tax profit-$86M$131M$107M-$224M-$173M
Free Cash FlowCash after capex-$73M$97M$161M-$183M-$48M
Gross MarginGross profit ÷ Revenue+48.3%+85.8%+67.5%+21.8%+75.2%
Operating MarginEBIT ÷ Revenue-5.3%+5.6%+13.4%-8.3%-27.2%
Net MarginNet income ÷ Revenue-5.3%+14.3%+7.5%-13.9%-25.7%
FCF MarginFCF ÷ Revenue-4.5%+10.6%+11.2%-11.3%-7.1%
Rev. Growth (YoY)Latest quarter vs prior year+5.9%+1.6%+14.3%+143.4%+12.3%
EPS Growth (YoY)Latest quarter vs prior year+38.3%-5.0%+106.7%-51.5%-100.0%
LIVN leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

LIVN leads this category, winning 3 of 6 comparable metrics.

At 8.7x trailing earnings, INSP trades at a 92% valuation discount to AVAV's 110.1x P/E. On an enterprise value basis, LIVN's 17.4x EV/EBITDA is more attractive than AVAV's 104.4x.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCAVAV logoAVAVAeroVironment, In…NVCR logoNVCRNovoCure Limited
Market CapShares × price$52M$1.2B$4.4B$8.5B$2.0B
Enterprise ValueMkt cap + debt − cash$66M$1.2B$4.2B$8.5B$2.2B
Trailing P/EPrice ÷ TTM EPS-0.51x8.73x-17.84x110.05x-14.57x
Forward P/EPrice ÷ next-FY EPS est.47.59x18.68x59.24x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.83x17.39x104.43x
Price / SalesMarket cap ÷ Revenue4.48x1.35x3.14x10.38x3.09x
Price / BookPrice ÷ Book value/share0.93x1.63x3.61x5.42x5.82x
Price / FCFMarket cap ÷ FCF15.68x25.18x
LIVN leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

INSP leads this category, winning 6 of 9 comparable metrics.

INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-164 for NYXH. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to NYXH's 0.86x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs NYXH's 2/9, reflecting strong financial health.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCAVAV logoAVAVAeroVironment, In…NVCR logoNVCRNovoCure Limited
ROE (TTM)Return on equity-164.4%+18.0%+9.1%-6.4%-50.8%
ROA (TTM)Return on assets-80.8%+15.2%+4.2%-5.0%-16.5%
ROICReturn on invested capital-76.4%+6.0%+11.5%+3.6%-16.4%
ROCEReturn on capital employed-80.4%+6.7%+10.2%+4.5%-28.9%
Piotroski ScoreFundamental quality 0–927535
Debt / EquityFinancial leverage0.86x0.04x0.39x0.07x0.85x
Net DebtTotal debt minus cash$12M-$73M-$162M$23M$187M
Cash & Equiv.Liquid assets$30M$105M$636M$41M$103M
Total DebtShort + long-term debt$42M$32M$473M$64M$290M
Interest CoverageEBIT ÷ Interest expense-32.73x418.58x5.18x-5.99x-96.80x
INSP leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

AVAV leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in AVAV five years ago would be worth $15,065 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LIVN leads with a +70.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors AVAV at 20.8% vs INSP's -48.0% — a key indicator of consistent wealth creation.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCAVAV logoAVAVAeroVironment, In…NVCR logoNVCRNovoCure Limited
YTD ReturnYear-to-date-69.1%-53.7%+30.9%-33.4%+35.5%
1-Year ReturnPast 12 months-81.6%-66.8%+70.3%-10.3%-2.3%
3-Year ReturnCumulative with dividends-82.4%-85.9%+65.4%+76.1%-59.8%
5-Year ReturnCumulative with dividends-94.9%-77.3%-2.8%+50.6%-91.9%
10-Year ReturnCumulative with dividends-94.2%+70.9%+62.7%+445.9%+62.1%
CAGR (3Y)Annualised 3-year return-44.0%-48.0%+18.3%+20.8%-26.2%
AVAV leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — INSP and LIVN each lead in 1 of 2 comparable metrics.

INSP is the less volatile stock with a 1.16 beta — it tends to amplify market swings less than NVCR's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCAVAV logoAVAVAeroVironment, In…NVCR logoNVCRNovoCure Limited
Beta (5Y)Sensitivity to S&P 5002.10x1.16x1.23x1.90x2.21x
52-Week HighHighest price in past year$8.59$147.03$80.73$417.86$18.92
52-Week LowLowest price in past year$1.26$38.91$41.02$156.29$9.82
% of 52W HighCurrent price vs 52-week peak+16.2%+29.0%+98.3%+40.8%+94.0%
RSI (14)Momentum oscillator 0–10025.843.369.449.457.1
Avg Volume (50D)Average daily shares traded189K950K727K1.1M1.5M
Evenly matched — INSP and LIVN each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: NYXH as "Buy", INSP as "Hold", LIVN as "Buy", AVAV as "Buy", NVCR as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs -0.2% for LIVN (target: $79).

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…LIVN logoLIVNLivaNova PLCAVAV logoAVAVAeroVironment, In…NVCR logoNVCRNovoCure Limited
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuyBuy
Price TargetConsensus 12-month target$6.00$57.36$79.25$292.20$33.50
# AnalystsCovering analysts527142815
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+14.2%+0.1%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

LIVN leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). INSP leads in 1 (Profitability & Efficiency). 1 tied.

Best OverallLivaNova PLC (LIVN)Leads 2 of 6 categories
Loading custom metrics...

NYXH vs INSP vs LIVN vs AVAV vs NVCR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NYXH or INSP or LIVN or AVAV or NVCR a better buy right now?

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 8. 7x trailing P/E (47. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NYXH or INSP or LIVN or AVAV or NVCR?

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 8. 7x versus AeroVironment, Inc. at 110. 1x. On forward P/E, LivaNova PLC is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — NYXH or INSP or LIVN or AVAV or NVCR?

Over the past 5 years, AeroVironment, Inc.

(AVAV) delivered a total return of +50. 6%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: AVAV returned +445. 9% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NYXH or INSP or LIVN or AVAV or NVCR?

By beta (market sensitivity over 5 years), Inspire Medical Systems, Inc.

(INSP) is the lower-risk stock at 1. 16β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately 91% more volatile than INSP relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 86% for Nyxoah S. A. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NYXH or INSP or LIVN or AVAV or NVCR?

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NYXH or INSP or LIVN or AVAV or NVCR?

Inspire Medical Systems, Inc.

(INSP) is the more profitable company, earning 15. 9% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIVN leads at 14. 4% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NYXH or INSP or LIVN or AVAV or NVCR more undervalued right now?

On forward earnings alone, LivaNova PLC (LIVN) trades at 18.

7x forward P/E versus 59. 2x for AeroVironment, Inc. — 40. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

08

Which pays a better dividend — NYXH or INSP or LIVN or AVAV or NVCR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is NYXH or INSP or LIVN or AVAV or NVCR better for a retirement portfolio?

For long-horizon retirement investors, Inspire Medical Systems, Inc.

(INSP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16)). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INSP: +70. 9%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NYXH and INSP and LIVN and AVAV and NVCR?

These companies operate in different sectors (NYXH (Healthcare) and INSP (Healthcare) and LIVN (Healthcare) and AVAV (Industrials) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NYXH is a small-cap high-growth stock; INSP is a small-cap deep-value stock; LIVN is a small-cap quality compounder stock; AVAV is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.